Hydroxyurea (Standard)

CAT: 804-HY-B0313R-01Size: 10 mgDry Ice: NoHazardous: No
10 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Hydroxyurea (Standard) is the analytical standard of Hydroxyurea. This product is intended for research and analytical applications. Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase. Hydroxyurea shows anti-orthopoxvirus activity.
CAS Number
[127-07-1]
Product Name Alternative
Hydroxycarbamide (Standard)
UNSPSC
12352211
Target
Apoptosis; Autophagy; DNA/RNA Synthesis; HIV; Orthopoxvirus; Reference Standards
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Others
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hydroxyurea-standard.html
Purity
97.96
Smiles
O=C(N)NO
Molecular Formula
CH4N2O2
Molecular Weight
76.05
References & Citations
[1]Kovacic P, et al. Hydroxyurea (therapeutics and mechanism) : metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76 (1) :24-31.|[2]Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33 (12) :1486-92.|[3]Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.|[4]Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95 (9) :1599-603.|[5]M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60 (2) :506-14. |[6]Kovacic P, et al. Hydroxyurea (therapeutics and mechanism) : metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76 (1) :24-31.|[7]Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33 (12) :1486-92.|[8]Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.|[9]Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95 (9) :1599-603.|[10]M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 1986 Nov;60 (2) :506-14.
Shipping Conditions
Blue Ice
Storage Conditions
4°C, sealed storage, away from light and moisture
Scientific Category
Reference Standards
Clinical Information
Launched